Drug Profile
Research programme: diabetes therapeutics - Theracos
Alternative Names: CLX-0100; CLX-0940; THR-0100; THR-0940Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Calyx Therapeutics (CEASED)
- Developer Theracos
- Class Peptides; Stilbenes
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 09 Nov 2009 Preclinical development for type-2 diabetes mellitus is ongoing
- 31 May 2003 Theracos acquires assets from Calyx Therapeutics